Clinical trial Recruiting at 3 sites Observational Ages 18 and up

Evaluating real-world effectiveness of endovascular thrombectomy for stroke in the Asia-Pacific region

Official title: Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific: a Multicenter, Prospective Registry (ENDURE-APAC)

Run by Chinese University of Hong Kong · NCT05578300 · Data updated 2026-11-12

This study is testing how well a procedure called endovascular thrombectomy works for adults with a certain type of stroke in real-life situations across the Asia-Pacific region.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment350 (estimated)
SponsorChinese University of Hong Kong
Academic / other
Drugs / interventionserenumab
Locations3 sites (Linyi, Shandong and 2 other locations)
StatusRecruiting
StartedOctober 21, 2022
Main results expectedOctober 20, 2032
Study endsDecember 31, 2032
Registry record updatedMarch 18, 2026
Trial IDNCT05578300 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults over 18 years old with ischemic stroke and suspected large vessel occlusion.

Probably not a fit

Patients with isolated vertebral artery occlusion not involving the basilar artery will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the real-world implementation of endovascular thrombectomy (EVT) for patients with ischemic stroke and suspected large vessel occlusion (LVO) across multiple centers in the Asia-Pacific region. The study will recruit patients over 18 years of age who are undergoing EVT triage and will collect demographic and clinical data to evaluate factors influencing the effectiveness of EVT. By capturing data on patients who could not undergo EVT, the study seeks to identify gaps between clinical trial results and real-world practice. The findings may inform healthcare policies and improve treatment protocols for stroke patients.

Why it matters

Potential benefit: If successful, this study could enhance the implementation of EVT, leading to better outcomes for stroke patients in real-world settings.

How similar studies have gone: While there have been successful studies on EVT in controlled environments, this study aims to explore its effectiveness in real-world settings, making it a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient who are over 18 years of age.
* Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA).

Exclusion Criteria:

* Patient with isolated vertebral artery occlusion not involving the BA.

Where it's running

  • Linyi People's Hospital
    Linyi, Shandong, China
    Recruiting
  • The Affiliated Hospital of Medical College of Qingdao University
    Qingdao, Shandong, China
    Recruiting
  • Chinese University of Hong Kong
    Hong Kong, Hong Kong
    Recruiting

Study contacts

  • Principal investigator: Bonaventure Yiu Ming IP, MB ChB — Chinese University of Hong Kong
  • Study coordinator: Bonaventure Yiu Ming IP, MB ChB
  • Email: bonaventureip@cuhk.edu.hk
  • Phone: 852-28902002

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.